Ixmyelocel-T

Drug Profile

Ixmyelocel-T

Alternative Names: Bone Repair Cells - Vericel Corporation; BRC therapy - Vericel Corporation; Cardiac Repair Cells - Vericel Corporation; CRC therapy - Vericel Corporation; Tissue Repair Cells - Vericel Corporation; Tissue repair stem cell therapy - Vericel Corporation; TRC therapy - Vericel Corporation; Vascular Repair Cells - Vericel Corporation; VRC therapy - Vericel Corporation

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Aastrom Biosciences
  • Developer Aastrom Biosciences; University of Michigan; Vericel Corporation
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteonecrosis; Dilated cardiomyopathy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alveolar bone loss; Dilated cardiomyopathy
  • Preclinical Atherosclerosis
  • Suspended Peripheral ischaemia
  • No development reported Neurodegenerative disorders
  • Discontinued Non-union fracture; Osteoarthritis; Osteonecrosis; Osteoporosis; Vertebral fracture

Most Recent Events

  • 10 May 2017 Ixmyelocel-T receives Regenerative Medicine Advanced Therapy (RMAT) designation from US FDA for Dilated cardiomyopathy
  • 21 Feb 2017 Ixmyelocel-T receives Fast Track designation for Dilated cardiomyopathy [IM,Injection] in USA
  • 14 Nov 2016 Updated efficacy and adverse events data from the phase IIb ixCELL-DCM trial in Dilated cardiomyopathy released by Vericel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top